Co-stimulation agonists as a new immunotherapy for autoimmune diseases.
Co-stimulation agonists as a new immunotherapy for autoimmune diseases.
复制标题
共刺激激动剂作为自身免疫性疾病的新型免疫疗法。
DOI：
10.1016/j.molmed.2003.09.011
复制
发表时间：
2003
影响因子：
13.6
通讯作者：
Fu,Yang-Xin
中科院分区：
文献类型：
--
作者：
Sun,Yonglian;Subudhi,SumitK;Fu,Yang-Xin
淋巴细胞在许多自身免疫性疾病的发病机制中起重要作用。阻断T细胞激活的共刺激信号已被广泛用作治疗自身免疫的一种方法，但其临床成功有限。一些激动型抗共刺激分子的单抗能显著增强T细胞介导的免疫应答，如抗病毒、抗肿瘤和同种异体反应。令人惊讶的是，最近的研究表明，这些激动剂通过潜在地耗尽自身反应性淋巴细胞或抑制其功能，对自身免疫性疾病具有深远的治疗效果。这些发现表明，通过共刺激分子传递信号可以在调节免疫反应方面产生截然不同的结果，从而为自身免疫性疾病的治疗提供了一种新的方法。
Lymphocytes are important in the pathogenesis of many autoimmune diseases. Blocking co-stimulatory signals for T-cell activation has been widely used as an approach to treating autoimmunity, but it has encountered limited clinical success. Some agonistic monoclonal antibodies to co-stimulatory molecules greatly enhance immune responses mediated by T cells, such as antiviral, anti-tumor and alloresponses. Surprisingly, recent studies have demonstrated that these agonists have profound therapeutic effects on autoimmune diseases by potentially depleting autoreactive lymphocytes or by inhibiting their function. These findings imply that signaling through co-stimulatory molecules can have diametric outcomes in modulating immune responses, thereby providing a novel approach to the treatment of autoimmune diseases.